The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism

Trial Profile

The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs Paricalcitol (Primary) ; Paricalcitol (Primary) ; Alfacalcidol; Cinacalcet; Doxercalciferol
  • Indications Hyperparathyroidism
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms IMPACT SHPT
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Apr 2014 Integrated data from the European Clinical Trials Database record.
    • 09 Apr 2014 Integrated data from the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top